Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

COBRA: ctDNA as a predictive biomarker for adjuvant chemotherapy in stage IIA colon cancer

Phase 2/3 trial of whether ctDNA detection after resection of stage IIA colon cancer identifies patients who benefit from adjuvant chemotherapy. ClinicalTrials.gov lists the study as active, not recruiting.

NRG Oncology